MONEY MASTER

China State Construction Engineering (SHSE:601668) has seen its stock climb 43% over the past five years, but its financials suggest investors should tread carefully. Key Metric: ROCE Falling Return on Capital Employed (ROCE):  6.8%, based on the latest 12 months. Down from  9.6% five years ago , signaling a decline in profitability from its capital investments. ROCE is roughly in line with the construction industry average of  5.7% , but low in absolute terms. Capital Use vs. Returns The company has been deploying more capital, yet sales haven’t grown significantly in the last year. This suggests ongoing long-term investments that may take time to yield results. High Liabilities Add Risk Current liabilities:  55% of total assets. Heavy reliance on short-term creditors raises operational risk. A lower ratio would indicate stronger financial stability. Takeaway While China State Construction Engineering is reinvesting in its business, declining returns and high liabil...

Shares of Tangshan Jidong Cement just jumped 30% this month  — but before you chase the rally, take a closer look. Despite the price spike, this might not be a growth story. In fact,  this cement stock is trading at a humble P/S of just 0.6x , well below its Basic Materials peers in China, many of which trade  above 1.6x  — and some over  5x . So is this a screaming value buy? Or is the market sending a warning? What’s Beneath the Surface? Last 12 months revenue: -2.1% 3-year revenue trend: -29% total Forward revenue growth estimate: just +0.6%  (vs industry +8.1%) Those numbers tell a tough story: this isn’t a high-growth business anymore. What’s Driving the Low Valuation? Revenue is shrinking , and even bullish analysts don’t see a strong rebound. The market sees better growth elsewhere  in the Basic Materials space. Investors are cautious , pricing in stagnation — or worse, another leg down. Still, with a low P/S and recent price surge,  some c...

Not all rallies scream with hype. Some, like  Harbin Pharmaceutical Group , climb quietly — backed not by noise, but by  solid fundamentals . +11% in the past month. 57% earnings growth over five years. ROE of 11% vs. industry average of 7.1%. These aren’t meme metrics — these are the  hallmarks of a business executing well  behind the scenes. What’s Driving It? Efficient capital use : For every ¥1 in equity, Harbin Pharma returns ¥0.11 in profit. Reinvesting 100%  of its earnings. No dividends. Just pure business reinvestment. Outpaced its industry : While peers averaged 6.2% net income growth, Harbin clocked in 57%. That’s the kind of compounding investors dream of — and rarely find without digging. But Here’s the Twist… Analysts expect earnings growth to  slow down . Whether that’s a sector-wide sentiment shift or a real red flag depends on how well management can continue allocating capital effectively. Stock Picker’s Take: This is a  “sleep well a...

In a market where fundamentals often drive price action,  Shenzhen InfoGem Technologies  is rewriting the script — and setting off alarm bells (or excitement?) for momentum traders and contrarian investors alike. 445% gain in a year. 320% in three years. And a fresh 5.8% just this week. Yet here’s the kicker —  its revenue actually shrank by 13% in the past year . No earnings. No booming top-line growth. Just pure, speculative firepower. So what’s really behind the rally? Speculation or Strategic Shift? While fundamentals haven’t caught up, sentiment certainly has. Some clues: Market betting on  future tech pivot or policy advantage ? CEO pay is modest — often a good governance signal.  Could AI, quantum tech or digital government contracts be in the cards? This isn't a value investor’s darling — it’s a  "market sentiment rocket" . But as any seasoned investor knows: sometimes the crowd runs ahead of the curve for a reason. Stock Picker's Take: If you belie...

China’s runaway stock rally came to a halt on Wednesday, with commodities struggling as investors tempered their expectations for a robust Chinese economic recovery. This pressure spread across global shares , causing concerns about sustained growth. China's benchmark indexes saw their largest daily losses since the start of the pandemic. Shanghai stocks dropped 6.6% , and blue-chips fell 7.1% , ending a 10-day winning streak. The pullback followed a news conference by China's National Development and Reform Commission , which failed to deliver significant new stimulus details. Investor attention is now shifting to China's finance ministry , set to hold a news conference on Saturday , expected to unveil fiscal stimulus plans . Markets anticipate a spending package between two and 10 trillion yuan (US$280 billion to US$1.4 trillion) to boost the economy. Despite the slowdown, some market players remain optimistic. Alexandre Marquis of Unigestion pointed out that domesti...

Chinese equities experienced their biggest weekly rally since 2008, as a massive wave of buying overwhelmed the Shanghai stock exchange on Friday. The CSI 300 Index surged 4.5% , bringing its weekly gain to 16% , following a series of economic stimulus measures announced by Xi Jinping's government . Trading was so intense that it caused glitches and delays in processing orders, prompting the Shanghai exchange to investigate. This burst of activity signals a shift in investor sentiment after years of losses, with China's US$8.9 trillion stock market having been one of the world's worst performers. Earlier in the week, Chinese authorities launched a much-anticipated monetary stimulus package and pledged further support for the housing market and consumption . Although the details of the stimulus plan are still emerging, many investors are afraid of missing out on a potential sustained rally . As domestic markets close for Golden Week holidays , investors are eager ...